Hikma Pharmaceuticals Share News (HIK)

Wednesday broker round-up UPDATE

Aviva: Nomura moves target price from 474p to 489p retaining a buy recommendation. Bellway: Numis upgrades to buy with a target price of 1690p. Breedon Aggregates: Jefferies starts with a target price of 42p and a buy recommendation. Britvic: UBS ups target price from 575p to 600p and keeps a neu

UK BROKER RATING CHANGES: Citi Raises Rio Tinto Target, Cuts Other Miners

MARKET PULSE-J.C. Penney, voxeljet, La-Z-Boy, gold stocks, Clovis

(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s); for the Morning News Call newsletter, http://link.reuters.com/nex49s) The Dow and S&P 500 dipped on Wednesday after minutes from a Federal Reserve policy meeting said

UK WINNERS & LOSERS: Aberdeen Gains Some More, Barclays Likes Barratt

Hikma Pharmaceuticals Signs Exclusive Agreement For Unilife Pre-Filled Syringes

Hikma signs syringe supply deal with Unilife Corp

Pharmaceuticals group Hikma has signed a 15-year commercial supply deal with US firm Unilife Corporation for the use of its Unifill prefilled syringes. Pennsylvania-based Unilife will supply Hikma with customised prefillable syringes to be used with a range of the FTSE 250 group's generic injectabl

DIRECTOR DEALINGS: Hikma Pharmaceutical US CEO Sells Shares

Carillion Finance Director lowers holding

Carillion's Group Finance Director, Richard Adam, on Thursday sold, on behalf of his wife, 40,000 shares. Each of these was sold for 309.04p, for a total trade value of £123,616. Adam's stake now stands at 118,238 shares. The disposal was made a week after the support services company announced

DIRECTOR DEALINGS: Hikma Pharma CEO Excercises Options, Acquires Shares

BROKER RATING CHANGES: JP Morgan Raises Schroders Price Target

Friday broker round-up UPDATE

Abcam: Canaccord Genuity moves target price from 396p to 386p and keeps a sell recommendation. N+1 Singer shifts target price from 450p to 445p downgrading to sell. Aberdeen Asset Management: Jefferies lowers target price from 440p to 430p and reiterates a hold recommendation. Anglo American: Gold

Hikma Pharmaceuticals Maintains Revenue Growth Guidance Of 20%

MARKET COMMENT: UK Stocks Set To Open Lower Ahead Of US Non-Farm Payrolls

Hikma Pharmaceuticals expects annual revenue growth

Hikma Pharmaceuticals said it is maintaining its guidance for 2013 for 20 per cent revenue growth on the back of a strong performance across all its divisions. The group's global Injectables business has delivered robust results, particularly in the US, where growth is being driven by demand acros

Hikma raises generics unit forecast on strong doxycycline sales

Nov 8 (Reuters) - Hikma Pharmaceuticals Plc said it expects full-year revenue growth of 20 percent and raised its sales forecast for its generics unit as sales of antibiotic doxycycline continued to soar. The drugmaker now expects full-year sales in its generic unit to be about $260 million